NCT06846606 2026-03-03Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDSAuron Therapeutics, Inc.Phase 1 Active not recruiting34 enrolled
NCT06325748 2026-02-12SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDSSenti BiosciencesPhase 1 Active not recruiting21 enrolled
NCT02598661 2026-01-05Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Geron CorporationPhase 2/3 Active not recruiting289 enrolled 35 charts 1 FDA
NCT05564650 2025-12-08Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic SyndromeThomas Jefferson UniversityPhase 1 Active not recruiting6 enrolled
NCT01552434 2025-10-14Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseM.D. Anderson Cancer CenterPhase 1 Active not recruiting155 enrolled
NCT00544115 2025-06-10Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersCity of Hope Medical CenterPhase 2 Active not recruiting260 enrolled 13 charts